Search

Your search keyword '"Brugts, Jasper J."' showing total 729 results
Start Over Author "Brugts, Jasper J."
729 results on '"Brugts, Jasper J."'

11. Impact of progressive aortic regurgitation on outcomes after left ventricular assist device implantation

Author

Gasparovic, Hrvoje, Jakus, Nina, Brugts, Jasper J., Pouleur, Anne-Catherine, Timmermans, Philippe, Rubiś, Pawel, Gaizauskas, Edvinas, Van Craenenbroeck, Emeline M., Barge-Caballero, Eduardo, Grundmann, Sebastian, Paolillo, Stefania, D’Amario, Domenico, Braun, Oscar Ö., Meyns, Bart, Droogne, Walter, Wierzbicki, Karol, Holcman, Katarzyna, Planinc, Ivo, Lovric, Daniel, Flammer, Andreas J., Petricevic, Mate, Biocina, Bojan, Lund, Lars H., Milicic, Davor, Ruschitzka, Frank, and Cikes, Maja

Published
2022
Full Text
View/download PDF

13. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial

Author

Emans, M E, Beeres, S L M A, Heerebeek, L, Kirchhof, C, Van Ramshorst, J, Spee, R, Smilde, T, Van Eck, M, Kaplan, E, Hazeleger, R, Tukkie, R, Feenema, M, Kok, W, Van Halm, V, Handoko, M L, Van Kimmenade, R, Post, M, Van Mieghem, N, Manintveld, O C, Brugts, Jasper J, Radhoe, Sumant P, Clephas, Pascal R D, Aydin, Dilan, van Gent, Marco W F, Szymanski, Mariusz K, Rienstra, Michiel, van den Heuvel, Mieke H, da Fonseca, Carlos A, Linssen, Gerard C M, Borleffs, C Jan Willem, Boersma, Eric, Asselbergs, Folkert W, Mosterd, Arend, Brunner-La Rocca, Hans-Peter, and de Boer, Rudolf A

Published
2023
Full Text
View/download PDF

14. Contemporary guideline‐directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE‐HF study

Author

Malgie, Jishnu, primary, Wilde, Mariëlle I., additional, Clephas, Pascal R.D., additional, Emans, Mireille E., additional, Koudstaal, Stefan, additional, Schaap, Jeroen, additional, Mosterd, Arend, additional, van Ramshorst, Jan, additional, Wardeh, Alexander J., additional, van Wijk, Sandra, additional, van den Heuvel, Mieke, additional, Wierda, Eric, additional, Borleffs, C. Jan Willem, additional, Saraber, Colette, additional, Beeres, Saskia L.M.A., additional, van Kimmenade, Roland, additional, Jansen Klomp, Wouter, additional, Denham, Robert, additional, da Fonseca, Carlos A., additional, Klip, IJsbrand T., additional, Manintveld, Olivier C., additional, van der Boon, Robert M.A., additional, van Ofwegen, Clara E.E., additional, Yilmaz, Ayten, additional, Pisters, Ron, additional, Linssen, Gerard C.M., additional, Faber, Nikola, additional, van Heerebeek, Loek, additional, van de Swaluw, Julio E.C., additional, Bouhuijzen, Lex J., additional, Post, Marco C., additional, Kuijper, Aaf F.M., additional, Wu, Ka wai, additional, van Beek, Eugène A., additional, Hesselink, Tim, additional, Kleijn, Lennaert, additional, Kurvers, Maurice J.M., additional, Tio, René A., additional, Langerveld, Jorina, additional, van Dalen, Bas M., additional, van Eck, J.W. Martijn, additional, Handoko, M. Louis, additional, Hermans, Walter R.M., additional, Koornstra‐Wortel, Hetty J.J., additional, Szymanski, Mariusz K., additional, Rooker, Dennis, additional, Tandjung, Kenneth, additional, Eijsbouts, Sabine C.M., additional, Asselbergs, Folkert W., additional, van der Meer, Peter, additional, Brunner‐La Rocca, Hans‐Peter, additional, de Boer, Rudolf A., additional, and Brugts, Jasper J., additional

Published
2024
Full Text
View/download PDF

25. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

Author

Rahimi, Kazem, Bidel, Zeinab, Nazarzadeh, Milad, Copland, Emma, Canoy, Dexter, Wamil, Malgorzata, Majert, Jeannette, McManus, Richard, Adler, Amanda, Agodoa, Larry, Algra, Ale, Asselbergs, Folkert W, Beckett, Nigel S, Berge, Eivind, Black, Henry, Boersma, Eric, Brouwers, Frank P J, Brown, Morris, Brugts, Jasper J, Bulpitt, Christopher J, Byington, Robert P, Cushman, William C, Cutler, Jeffrey, Devereaux, Richard B, Dwyer, Jamie P, Estacio, Ray, Fagard, Robert, Fox, Kim, Fukui, Tsuguya, Gupta, Ajay K, Holman, Rury R, Imai, Yutaka, Ishii, Masao, Julius, Stevo, Kanno, Yoshihiko, Kjeldsen, Sverre E, Kostis, John, Kuramoto, Kizuku, Lanke, Jan, Lewis, Edmund, Lewis, Julia B, Lievre, Michel, Lindholm, Lars H, Lueders, Stephan, MacMahon, Stephen, Mancia, Giuseppe, Matsuzaki, Masunori, Mehlum, Maria H, Nissen, Steven, Ogawa, Hiroshi, Ogihara, Toshio, Ohkubo, Takayoshi, Palmer, Christopher R, Patel, Anushka, Pfeffer, Marc Allan, Pitt, Bertram, Poulter, Neil R, Rakugi, Hiromi, Reboldi, Gianpaolo, Reid, Christopher, Remuzzi, Giuseppe, Ruggenenti, Piero, Saruta, Takao, Schrader, Joachim, Schrier, Robert, Sever, Peter, Sleight, Peter, Staessen, Jan A, Suzuki, Hiromichi, Thijs, Lutgarde, Ueshima, Kenji, Umemoto, Seiji, van Gilst, Wiek H, Verdecchia, Paolo, Wachtell, Kristian, Whelton, Paul, Wing, Lindon, Woodward, Mark, Yui, Yoshiki, Yusuf, Salim, Zanchetti, Alberto, Zhang, Zhen-Yu, Anderson, Craig, Baigent, Colin, Brenner, Barry Morton, Collins, Rory, de Zeeuw, Dick, Lubsen, Jacobus, Malacco, Ettore, Neal, Bruce, Perkovic, Vlado, Rodgers, Anthony, Rothwell, Peter, Salimi-Khorshidi, Gholamreza, Sundström, Johan, Turnbull, Fiona, Viberti, Giancarlo, Wang, Jiguang, Chalmers, John, Davis, Barry R, Pepine, Carl J, and Teo, Koon K

Published
2021
Full Text
View/download PDF

27. Abstract 12012: Subphenotypes of Heart Failure With Reduced Ejection Fraction Based on Repeated Measurements of 4210 Circulating Proteins Are Driven by Protein Subsets Reflecting Different Biological Mechanisms

Author

Petersen, Teun B, de Bakker, Marie, Asselbergs, Folkert W, Akkerhuis, K. Martijn, Brugts, Jasper J, van Ramshorst, Jan, Lumbers, Tom, Ostroff, Rachel, Katsikis, Peter D, van der Spek, Peter J, Umans, Victor A, Boersma, Eric, Rizopoulos, Dimitris, and Kardys, Isabella

Published
2022
Full Text
View/download PDF

29. Guideline implementation, drug sequencing, and quality of care in heart failure:design and rationale of TITRATE-HF

Author

Clephas, Pascal R.D., Malgie, Jishnu, Schaap, Jeroen, Koudstaal, Stefan, Emans, Mireille, Linssen, Gerard C.M., de Boer, Grytsje A., van Heerebeek, Loek, Borleffs, C. Jan Willem, Manintveld, Olivier C., van Empel, Vanessa, van Wijk, Sandra, van den Heuvel, Mieke, da Fonseca, Carlos, Damman, Kevin, van Ramshorst, Jan, van Kimmenade, Roland, van de Ven, Arjen R.T., Tio, René A., van Veghel, Dennis, Asselbergs, Folkert W., de Boer, Rudolf A., van der Meer, Peter, Greene, Stephen J., Brunner-La Rocca, Hans Peter, Brugts, Jasper J., Clephas, Pascal R.D., Malgie, Jishnu, Schaap, Jeroen, Koudstaal, Stefan, Emans, Mireille, Linssen, Gerard C.M., de Boer, Grytsje A., van Heerebeek, Loek, Borleffs, C. Jan Willem, Manintveld, Olivier C., van Empel, Vanessa, van Wijk, Sandra, van den Heuvel, Mieke, da Fonseca, Carlos, Damman, Kevin, van Ramshorst, Jan, van Kimmenade, Roland, van de Ven, Arjen R.T., Tio, René A., van Veghel, Dennis, Asselbergs, Folkert W., de Boer, Rudolf A., van der Meer, Peter, Greene, Stephen J., Brunner-La Rocca, Hans Peter, and Brugts, Jasper J.

Abstract

Aims: Current heart failure (HF) guidelines recommend to prescribe four drug classes in patients with HF with reduced ejection fraction (HFrEF). A clear challenge exists to adequately implement guideline-directed medical therapy (GDMT) regarding the sequencing of drugs and timely reaching target dose. It is largely unknown how the paradigm shift from a serial and sequential approach for drug therapy to early parallel application of the four drug classes will be executed in daily clinical practice, as well as the reason clinicians may not adhere to new guidelines. We present the design and rationale for the real-world TITRATE-HF study, which aims to assess sequencing strategies for GDMT initiation, dose titration patterns (order and speed), intolerance for GDMT, barriers for implementation, and long-term outcomes in patients with de novo, chronic, and worsening HF. Methods and results: A total of 4000 patients with HFrEF, HF with mildly reduced ejection fraction, and HF with improved ejection fraction will be enrolled in >40 Dutch centres with a follow-up of at least 3 years. Data collection will include demographics, physical examination and vital parameters, electrocardiogram, laboratory measurements, echocardiogram, medication, and quality of life. Detailed information on titration steps will be collected for the four GDMT drug classes. Information will include date, primary reason for change, and potential intolerances. The primary clinical endpoints are HF-related hospitalizations, HF-related urgent visits with a need for intravenous diuretics, all-cause mortality, and cardiovascular mortality. Conclusions: TITRATE-HF is a real-world multicentre longitudinal registry that will provide unique information on contemporary GDMT implementation, sequencing strategies (order and speed), and prognosis in de novo, worsening, and chronic HF patients.

Published
2024

30. Embedding routine health care data in clinical trials:with great power comes great responsibility

Author

Handoko, M. Louis, de Man, Frances S., Brugts, Jasper J., van der Meer, Peter, Rhodius-Meester, Hanneke F.M., Schaap, Jeroen, van de Kamp, H. J.Rik, Houterman, Saskia, van Veghel, Dennis, Uijl, Alicia, Asselbergs, Folkert W., Handoko, M. Louis, de Man, Frances S., Brugts, Jasper J., van der Meer, Peter, Rhodius-Meester, Hanneke F.M., Schaap, Jeroen, van de Kamp, H. J.Rik, Houterman, Saskia, van Veghel, Dennis, Uijl, Alicia, and Asselbergs, Folkert W.

Abstract

Randomised clinical trials (RCTs) are vital for medical progress. Unfortunately, ‘traditional’ RCTs are expensive and inherently slow. Moreover, their generalisability has been questioned. There is considerable overlap in routine health care data (RHCD) and trial-specific data. Therefore, integration of RHCD in an RCT has great potential, as it would reduce the effort and costs required to collect data, thereby overcoming some of the major downsides of a traditional RCT. However, use of RHCD comes with other challenges, such as privacy issues, as well as technical and practical barriers. Here, we give a current overview of related initiatives on national cardiovascular registries (Netherlands Heart Registration, Heart4Data), showcasing the interrelationships between and the relevance of the different registries for the practicing physician. We then discuss the benefits and limitations of RHCD use in the setting of a pragmatic RCT from a cardiovascular perspective, illustrated by a case study in heart failure.

Published
2024

31. Sex-specific cardiovascular protein levels and their link with clinical outcome in heart failure

Author

de Bakker, Marie, Loncq de Jong, Mylène, Petersen, Teun, de Lange, Iris, Akkerhuis, K. Martijn, Umans, Victor A., Rizopoulos, Dimitris, Boersma, Eric, Brugts, Jasper J., Kardys, Isabella, de Bakker, Marie, Loncq de Jong, Mylène, Petersen, Teun, de Lange, Iris, Akkerhuis, K. Martijn, Umans, Victor A., Rizopoulos, Dimitris, Boersma, Eric, Brugts, Jasper J., and Kardys, Isabella

Abstract

Aims: This study aims to provide insight into sex-specific cardiovascular protein profiles and their associations with adverse outcomes, which may contribute to a better understanding of heart failure (HF) pathophysiology and the optimal use of circulating proteins for prognostication in women and men. Methods and results: In 250 stable patients with HF with reduced ejection fraction (HFrEF), we performed trimonthly blood sampling (median follow-up: 26 [17–30] months). We selected all baseline samples and two samples closest to the primary endpoint (PEP; composite of cardiovascular death, heart transplantation, left ventricular assist device implantation, and HF hospitalization) or one sample closest to censoring and applied the Olink Cardiovascular III panel. We used linear regression to study sex-based differences in baseline levels and joint models to study differences in the prognostic value of serially measured proteins. In 66 women and 184 men (mean age of 66 and 67 years, respectively), 21% and 28% reached the PEP, respectively. Mean baseline levels of fatty acid-binding protein 4, secretoglobin family 3A member 2, paraoxonase 3, and trefoil factor 3 were higher in women (Pinteraction: 0.001, 0.007, 0.018, and 0.049, respectively), while matrix metalloproteinase-3, interleukin 1 receptor-like 1, and myoglobin were higher in men (Pinteraction: <0.001, 0.001, and 0.049, respectively), independent of clinical characteristics. No significant differences between sexes were observed in the longitudinal associations of proteins with the PEP. Only peptidoglycan recognition protein 1 showed a suggestive interaction with sex for the primary outcome (Pinteraction = 0.028), without multiple testing correction, and was more strongly associated with adverse outcome in women {hazard ratio [HR] 3.03 [95% confidence interval (CI), 1.42 to 6.68], P = 0.008} compared with men [HR 1.18 (95% CI, 0.84 to 1.66), P = 0.347]. Conclusions: Althou

Published
2024

32. The different risk of new-onset, chronic, worsening, and advanced heart failure:A systematic review and meta-regression analysis

Author

Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., Brugts, Jasper J., Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., and Brugts, Jasper J.

Abstract

Aims: Heart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the different stages of HF, an overview of these risks is lacking. This study aims to determine the risk of all-cause mortality and HF hospitalizations associated with new-onset HF, chronic HF (CHF), worsening HF (WHF), and advanced HF. Methods and results: We performed a systematic review of observational studies from 2012 to 2022 using five different databases. The primary outcomes were 30-day and 1-year all-cause mortality, as well as 1-year HF hospitalization. Studies were pooled using random effects meta-analysis, and mixed-effects meta-regression was used to compare the different HF groups. Among the 15 759 studies screened, 66 were included representing 862 046 HF patients. Pooled 30-day mortality rates did not reveal a significant distinction between hospital-admitted patients, with rates of 10.13% for new-onset HF and 8.11% for WHF (p = 0.10). However, the 1-year mortality risk differed and increased stepwise from CHF to advanced HF, with a rate of 8.47% (95% confidence interval [CI] 7.24–9.89) for CHF, 21.15% (95% CI 17.78–24.95) for new-onset HF, 26.84% (95% CI 23.74–30.19) for WHF, and 29.74% (95% CI 24.15–36.10) for advanced HF. Readmission rates for HF at 1 year followed a similar trend. Conclusions: Our meta-analysis of observational studies confirms the different risk for adverse outcomes across the distinct HF stages. Moreover, it emphasizes the negative prognostic value of WHF as the first progressive stage from CHF towards advanced HF.

Published
2024

33. Embedding routine health care data in clinical trials: with great power comes great responsibility

Author

Cardiometabolic Health, Handoko, M Louis, de Man, Frances S, Brugts, Jasper J, van der Meer, Peter, Rhodius-Meester, Hanneke F M, Schaap, Jeroen, van de Kamp, H J Rik, Houterman, Saskia, van Veghel, Dennis, Uijl, Alicia, Asselbergs, Folkert W, Cardiometabolic Health, Handoko, M Louis, de Man, Frances S, Brugts, Jasper J, van der Meer, Peter, Rhodius-Meester, Hanneke F M, Schaap, Jeroen, van de Kamp, H J Rik, Houterman, Saskia, van Veghel, Dennis, Uijl, Alicia, and Asselbergs, Folkert W

Published
2024

34. Cost-effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS-HF system) in chronic heart failure in the Netherlands

Author

Mokri, Hamraz, Clephas, Pascal R.D., de Boer, Rudolf A., van Baal, Pieter, Brugts, Jasper J., Rutten-van Mölken, Maureen P.M.H., Mokri, Hamraz, Clephas, Pascal R.D., de Boer, Rudolf A., van Baal, Pieter, Brugts, Jasper J., and Rutten-van Mölken, Maureen P.M.H.

Abstract

Aims: Remote haemodynamic monitoring with an implantable pulmonary artery (PA) sensor has been shown to reduce heart failure (HF) hospitalizations and improve quality of life. Cost-effectiveness analyses studying the value of remote haemodynamic monitoring in a European healthcare system with a contemporary standard care group are lacking. Methods and results: A Markov model was developed to estimate the cost-effectiveness of PA-guided therapy compared to the standard of care based upon patient-level data of the MONITOR-HF trial performed in the Netherlands in patients with chronic HF (New York Heart Association class III and at least one previous HF hospitalization). Cost-effectiveness was measured as the incremental cost per quality-adjusted life year (QALY) gained from the Dutch societal perspective with a lifetime horizon which encompasses a wide variety of costs including costs of hospitalizations, monitoring time, telephone contacts, laboratory assessments, and drug changes in both treatment groups. In the base-case analysis, PA-guided therapy increased costs compared to standard of care by €12 121. The QALYs per patient for PA-guided therapy and standard of care was 4.07 and 3.481, respectively, reflecting a gain of 0.58 QALYs. The resulting incremental cost-effectiveness ratio was €20 753 per QALY, which is below the Dutch willingness-to-pay threshold of €50 000 per QALY gained for HF. Conclusions: The current cost-effectiveness study suggests that remote haemodynamic monitoring with PA-guided therapy on top of standard care is likely to be cost-effective for patients with symptomatic moderate-to-severe HF in the Netherlands.

Published
2024

37. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE‐HF

Author

Clephas, Pascal R. D., primary, Malgie, Jishnu, additional, Schaap, Jeroen, additional, Koudstaal, Stefan, additional, Emans, Mireille, additional, Linssen, Gerard C. M., additional, de Boer, Grytsje A., additional, van Heerebeek, Loek, additional, Borleffs, C. Jan Willem, additional, Manintveld, Olivier C., additional, van Empel, Vanessa, additional, van Wijk, Sandra, additional, van den Heuvel, Mieke, additional, da Fonseca, Carlos, additional, Damman, Kevin, additional, van Ramshorst, Jan, additional, van Kimmenade, Roland, additional, van de Ven, Arjen R. T., additional, Tio, René A., additional, van Veghel, Dennis, additional, Asselbergs, Folkert W., additional, de Boer, Rudolf A., additional, van der Meer, Peter, additional, Greene, Stephen J., additional, Brunner‐La Rocca, Hans‐Peter, additional, and Brugts, Jasper J., additional

Published
2023
Full Text
View/download PDF

39. Use of loop diuretics in patients with chronic heart failure: an observational overview

Author

Scholte, Niels TB, primary, Aydin, Dilan, additional, Linssen, Gerard CM, additional, Koudstaal, Stefan, additional, Rademaker, Philip C, additional, Geerlings, Peter R, additional, van Gent, Marco WF, additional, Aksoy, Ismail, additional, Oosterom, Liane, additional, Boersma, Eric, additional, Brunner-La Rocca, Hans-Peter, additional, and Brugts, Jasper J, additional

Published
2023
Full Text
View/download PDF

40. Remote haemodynamic monitoring and the next step: Involving the patient in the self‐management of heart failure.

Author

Brugts, Jasper J.

Subjects
*PATIENT compliance, *HEART failure, *ATRIAL septum, *HEART failure patients, *WATER-electrolyte balance (Physiology), *HEALTH self-care
Abstract

This article discusses the findings of the VECTOR-HF I and IIa studies, which examined the safety and performance of a left atrial pressure (LAP)-guided heart failure (HF) management system called V-LAP. The studies found that the system successfully achieved its primary endpoints, including the ability to perform LAP measurements and transmit data to healthcare providers. The use of physician-directed patient self-management (PSM) with the V-LAP system also showed potential for decreasing HF hospitalization rates and improving clinical outcomes. The article highlights the importance of remote haemodynamic monitoring and the potential for patient empowerment in HF treatment. However, further research is needed to address limitations and ensure the long-term reliability of the system. The article also emphasizes the promising opportunities and challenges in implementing remote haemodynamic monitoring, including the need for reimbursement and lowering costs. Overall, the findings suggest that involving patients in self-care and awareness of HF management can lead to better lifestyle, education, and medication compliance. Remote haemodynamic monitoring has the potential to deepen our understanding of worsening HF and benefit a larger group of patients. The future of these innovative technologies looks promising, with multiple devices becoming available and competition driving innovation and efficiency in HF care delivery. [Extracted from the article]

Published
2024
Full Text
View/download PDF

46. The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis.

Author

Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., and Brugts, Jasper J.

Subjects
HEART failure, PROGNOSIS, MORTALITY, DEATH rate, SCIENTIFIC observation, CONFIDENCE intervals
Abstract

Aims: Heart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the different stages of HF, an overview of these risks is lacking. This study aims to determine the risk of all‐cause mortality and HF hospitalizations associated with new‐onset HF, chronic HF (CHF), worsening HF (WHF), and advanced HF. Methods and results: We performed a systematic review of observational studies from 2012 to 2022 using five different databases. The primary outcomes were 30‐day and 1‐year all‐cause mortality, as well as 1‐year HF hospitalization. Studies were pooled using random effects meta‐analysis, and mixed‐effects meta‐regression was used to compare the different HF groups. Among the 15 759 studies screened, 66 were included representing 862 046 HF patients. Pooled 30‐day mortality rates did not reveal a significant distinction between hospital‐admitted patients, with rates of 10.13% for new‐onset HF and 8.11% for WHF (p = 0.10). However, the 1‐year mortality risk differed and increased stepwise from CHF to advanced HF, with a rate of 8.47% (95% confidence interval [CI] 7.24–9.89) for CHF, 21.15% (95% CI 17.78–24.95) for new‐onset HF, 26.84% (95% CI 23.74–30.19) for WHF, and 29.74% (95% CI 24.15–36.10) for advanced HF. Readmission rates for HF at 1 year followed a similar trend. Conclusions: Our meta‐analysis of observational studies confirms the different risk for adverse outcomes across the distinct HF stages. Moreover, it emphasizes the negative prognostic value of WHF as the first progressive stage from CHF towards advanced HF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Machine learning–based biomarker profile derived from 4210 serially measured proteins predicts clinical outcome of patients with heart failure

Author

de Bakker, Marie, primary, Petersen, Teun B, additional, Rueten-Budde, Anja J, additional, Akkerhuis, K Martijn, additional, Umans, Victor A, additional, Brugts, Jasper J, additional, Germans, Tjeerd, additional, Reinders, Marcel J T, additional, Katsikis, Peter D, additional, van der Spek, Peter J, additional, Ostroff, Rachel, additional, She, Ruicong, additional, Lanfear, David, additional, Asselbergs, Folkert W, additional, Boersma, Eric, additional, Rizopoulos, Dimitris, additional, and Kardys, Isabella, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results